PURPOSE OF REVIEW In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC). RECENT FINDINGS For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery. SUMMARY Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.

中文翻译：

---

肾癌的放射治疗选择。

综述目的 在这篇综述中，作者讨论了立体定向全身放射治疗 (SBRT) 在治疗原发性和转移性肾细胞癌 (RCC) 中的应用。最新研究结果 对于采用 SBRT 治疗的原发性肾细胞癌，局部控制估计>95%，3-4 级毒性限制在 ≤5%。治疗前与治疗后的肾小球滤过率差异约为7.7ml/min。对于采用 SBRT 治疗的转移性肾细胞癌，1 年局部控制约为 90%。任何 3-4 级毒性的发生率约为 1%。几项正在进行的试验正在评估 SBRT 联合治疗或代替全身治疗的情况。RCC 的治疗仍存在许多未知因素，包括肿瘤预后、治疗选择和治疗实施。摘要 对于原发性和转移性肾细胞癌患者，立体定向放射治疗是一种安全有效的治疗选择。